Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Allergan has chalked up some flattering safety data for abicipar as it refines the eye drug’s manufacturing processes in preparation of an impending BLA filing. But whether or how much that matters is still up for debate.
In an open-label, single-arm study, investigators reported that the incidence of intraocular inflammation was 8.9% — lower than the rate observed in prior Phase III studies, which hovered around 15%. The MAPLE trial recruited 123 age-related neovascular macular degeneration (or wet AMD) patients and administered the injection five times over 28 weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.